Anti-Canine PD-L1 [Clone JC071] - 100 μg

Each year, thousands of dogs are diagnosed with cancer. Canine cancers bear many of the hallmarks of human cancers including tissue location, tumor progression, and response to chemotherapy and radiation. Unfortunately, canine lymphocyte populations are not as well defined as human lymphocytes, and reagents that target immune checkpoint pathways are not yet widely available for veterinary research. Interruption of the programmed death 1 (PD-1) / programmed death ligand 1 (PD-L1) pathway is an established and effective therapeutic strategy in human oncology and may be effective for treating canine cancers as well.